<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821715</url>
  </required_header>
  <id_info>
    <org_study_id>THN102-201</org_study_id>
    <secondary_id>2015-005035-41</secondary_id>
    <nct_id>NCT02821715</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients</brief_title>
  <official_title>Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranexus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranexus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study is a 8-site, double-blind, randomised, placebo-controlled, 3-way&#xD;
      cross-over trial, involving 3 treatments with Modafinil 300 mg or the combination drug THN102&#xD;
      (Modafinil/Flecainide 300 /3 mg, Modafinil/Flecainide 300 /27 mg).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 3 double blind periods (2-week) follow a stabilisation period for modafinil at 300 mg/day&#xD;
      (open, 2-week) and are followed by a one-week washout period with the same modafinil dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
    <description>Range 0 to 24, low score indicates good outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>14-item Fatigue Scale</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
    <description>Fatigue scale is a rating scale completed by the participants at each visit starting from baseline to last visit; 14 questions to be ticked off by &quot;yes&quot; or &quot;No&quot; by the patient. 0 : No fatigue 14 : worst fatigue condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire EQ-5D (European Quality of Life EQ-5D) (Questionnaire Part)</measure>
    <time_frame>14 days after the beginning of the screening</time_frame>
    <description>EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).&#xD;
The EQ-5D assesses the status on the day of visit and not over the past week. It has two parts:&#xD;
The first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.&#xD;
The second part is a 100 mm VAS (EQ-VAS). An increase in VAS indicates an improvement in health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGI-C)</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
    <description>PGI-C is a scale completed by the participants starting from screening to last Last visit (all the visits).&#xD;
Participants have to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C) Global Impression</measure>
    <time_frame>14 days after the end of treatment period I</time_frame>
    <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for global impression the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>14 days</time_frame>
    <description>Beck Depression Inventory (BDI) evaluation for depressive symptoms (including suicidal thoughts). The scale is completed by the participants from baseline, to last visit (all except screening visit). The questionnaire contains 21 items. Each must be scored from 0 to 3, minimum score = 0, maximum score = 63. A high score indicates increased severity of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression for Severity (PGI-S) Global Score</measure>
    <time_frame>14 days</time_frame>
    <description>PGI-S us a scale filled by the participant from screening to last visit (all the visits) Participants have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C) Sleepiness</measure>
    <time_frame>14 days after the end of treatment period I</time_frame>
    <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for sleepiness&#xD;
the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C) Cataplexy</measure>
    <time_frame>14 days after the end of treatment period I</time_frame>
    <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for Cataplexy&#xD;
the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for Severity (CGI-S) Global Score</measure>
    <time_frame>14 days after the end of treatment period I</time_frame>
    <description>CGI-S is a scale completed by the investigator at each visit : Item global impression&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 normal-not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among hte most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for Severity (CGI-S) Sleepiness</measure>
    <time_frame>14 days after the end of treatment period I</time_frame>
    <description>CGI-S is a scale completed by the investigator at each visit for Sleepiness&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for Severity (CGI-S) Cataplexy</measure>
    <time_frame>14 days after the end of treatment period I</time_frame>
    <description>CGI-S is a scale completed by the investigator at each visit for Cataplexy&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D European Quality of Life EQ-5D (Visual Analogic Scale Part)</measure>
    <time_frame>14 days</time_frame>
    <description>EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).&#xD;
The EQ-5D is a questionnaire assessing the quality of life of the patient. It has two parts:&#xD;
The first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.&#xD;
The second part is a 100 mm Visual analogic scale (EQ-VAS). An higher score in VAS indicates a better health state.&#xD;
The questionnaire is assessed at baseline and all subsequent visits</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Narcolepsy</condition>
  <arm_group>
    <arm_group_label>Modafinil + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 300/3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 300/27</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator: Modafinil + placebo</intervention_name>
    <arm_group_label>Modafinil + placebo</arm_group_label>
    <other_name>Modafinil 300 mg</other_name>
    <other_name>Flecainide Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 300/3</intervention_name>
    <arm_group_label>THN102 300/3</arm_group_label>
    <other_name>Modafinil 300 mg</other_name>
    <other_name>Flecainide 3 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 300/27</intervention_name>
    <arm_group_label>THN102 300/27</arm_group_label>
    <other_name>Modafinil 300 mg</other_name>
    <other_name>Flecainide 27 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of narcolepsy type 1 (i.e. with cataplexy) or type 2&#xD;
             (without cataplexy) according to the International Classification of Sleep Disorders&#xD;
             (ICSD-3) criteria.&#xD;
&#xD;
          -  Body mass index &gt;18 kg/m2 and &lt;35 kg/m2.&#xD;
&#xD;
          -  Patients treated with modafinil at stable dosage for at least 2 months and still&#xD;
             complaining of excessive daily somnolence (EDS) despite the treatment&#xD;
&#xD;
          -  Epworth Sleepiness Scale (ESS) score should be ≥ 14/24 during the baseline period.&#xD;
&#xD;
        Main exclusion Criteria:&#xD;
&#xD;
          -  Patients with an untreated sleep apnea syndrome (respiratory disorder index &gt; 30/h) or&#xD;
             who have any other cause of daytime sleepiness as assessed on patient history.&#xD;
&#xD;
          -  Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as&#xD;
             Parkinson's disease, Alzheimer's disease, Huntington's Chorea, multiple sclerosis,&#xD;
             moderate or severe psychosis or dementia, bipolar illness, epilepsy, severe clinical&#xD;
             anxiety or depression, Beck Depression Inventory ≥ 21 or with suicidal risk (if item &gt;&#xD;
             0), or other problem that in the investigator's opinion would preclude the patient's&#xD;
             participation and completion of this trial or comprise reliable representation of&#xD;
             subjective symptoms.&#xD;
&#xD;
          -  Contraindication to flecainide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Dauvilliers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RespiSom</name>
      <address>
        <city>Erpent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lilles</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02821715/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02821715/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>54 patients were screened, 51 patients were randomized and 48 started the double-blind treatment period</recruitment_details>
      <pre_assignment_details>Study starts with open-label run in period with modafinil 300 mg/d. 51 patients met study inclusion/exclusion criteria and entered the run-in period, 48 subjects still fulfilled inclusion criteria after run-in and entered the double-blind period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 : ABC</title>
          <description>Treatment A : 300 mg modafinil + 0 mg flecainide per day Treatment B : 300 mg modafinil and 3 mg flecainide per day Treatment C: 300 mg modafinil and 27 mg flecainide per day&#xD;
Treatment period A, B and C duration = 2 weeks No wash out between each period</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 : BCA</title>
          <description>Treatment A : 300 mg modafinil + 0 mg flecainide per day Treatment B : 300 mg modafinil and 3 mg flecainide per day Treatment C: 300 mg modafinil and 27 mg flecainide per day&#xD;
Treatment period A, B and C duration = 2 weeks No wash out between each period</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: CAB</title>
          <description>Treatment A : 300 mg modafinil + 0 mg flecainide per day Treatment B : 300 mg modafinil and 3 mg flecainide per day Treatment C: 300 mg modafinil and 27 mg flecainide per day&#xD;
Treatment period A, B and C duration = 2 weeks No wash out between each period</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4: ACB</title>
          <description>Treatment A : 300 mg modafinil + 0 mg flecainide per day Treatment B : 300 mg modafinil and 3 mg flecainide per day Treatment C: 300 mg modafinil and 27 mg flecainide per day&#xD;
Treatment period A, B and C duration = 2 weeks No wash out between each period</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5: CBA</title>
          <description>Treatment A : 300 mg modafinil + 0 mg flecainide per day Treatment B : 300 mg modafinil and 3 mg flecainide per day Treatment C: 300 mg modafinil and 27 mg flecainide per day&#xD;
Treatment period A, B and C duration = 2 weeks No wash out between each period</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6: BAC</title>
          <description>Treatment A : 300 mg modafinil + 0 mg flecainide per day Treatment B : 300 mg modafinil and 3 mg flecainide per day Treatment C: 300 mg modafinil and 27 mg flecainide per day&#xD;
Treatment period A, B and C duration = 2 weeks No wash out between each period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Ethnicity data not collected at baseline</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants received either:&#xD;
A Modafinil 300mg/d/Flecainide placebo, B Modafinil 300mg/d/Flecainide 3mg/d C Modafinil 300mg/d/Flecainide 27mg/d</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>51 patients were randomised (1 randomized patient never took study medication), Safety set: 50 patients Modified Intent to Treat Set: 48 patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epworth Sleepiness Scale (ESS)</title>
          <description>Score from 0 to 24, high score = severe sleepiness</description>
          <population>Efficacy population (modified Intent to Treat Population) 48</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Epworth Sleepiness Scale (ESS)</title>
        <description>Range 0 to 24, low score indicates good outcome</description>
        <time_frame>14 days after the beginning of treatment period</time_frame>
        <population>modified Intent To Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS)</title>
          <description>Range 0 to 24, low score indicates good outcome</description>
          <population>modified Intent To Treat population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.68" spread="0.689"/>
                    <measurement group_id="O2" value="15.34" spread="0.695"/>
                    <measurement group_id="O3" value="15.34" spread="0.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>14-item Fatigue Scale</title>
        <description>Fatigue scale is a rating scale completed by the participants at each visit starting from baseline to last visit; 14 questions to be ticked off by &quot;yes&quot; or &quot;No&quot; by the patient. 0 : No fatigue 14 : worst fatigue condition</description>
        <time_frame>14 days after the beginning of treatment period</time_frame>
        <population>modified Intent To Treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>14-item Fatigue Scale</title>
          <description>Fatigue scale is a rating scale completed by the participants at each visit starting from baseline to last visit; 14 questions to be ticked off by &quot;yes&quot; or &quot;No&quot; by the patient. 0 : No fatigue 14 : worst fatigue condition</description>
          <population>modified Intent To Treat (mITT)</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="0.545"/>
                    <measurement group_id="O2" value="6.94" spread="0.549"/>
                    <measurement group_id="O3" value="7.25" spread="0.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Questionnaire EQ-5D (European Quality of Life EQ-5D) (Questionnaire Part)</title>
        <description>EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).&#xD;
The EQ-5D assesses the status on the day of visit and not over the past week. It has two parts:&#xD;
The first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.&#xD;
The second part is a 100 mm VAS (EQ-VAS). An increase in VAS indicates an improvement in health state.</description>
        <time_frame>14 days after the beginning of the screening</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Questionnaire EQ-5D (European Quality of Life EQ-5D) (Questionnaire Part)</title>
          <description>EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).&#xD;
The EQ-5D assesses the status on the day of visit and not over the past week. It has two parts:&#xD;
The first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.&#xD;
The second part is a 100 mm VAS (EQ-VAS). An increase in VAS indicates an improvement in health state.</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.358"/>
                    <measurement group_id="O2" value="1.16" spread="0.189"/>
                    <measurement group_id="O3" value="1.24" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Change (PGI-C)</title>
        <description>PGI-C is a scale completed by the participants starting from screening to last Last visit (all the visits).&#xD;
Participants have to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
        <time_frame>14 days after the beginning of treatment period</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Change (PGI-C)</title>
          <description>PGI-C is a scale completed by the participants starting from screening to last Last visit (all the visits).&#xD;
Participants have to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGI-C) Global Impression</title>
        <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for global impression the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
        <time_frame>14 days after the end of treatment period I</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change (CGI-C) Global Impression</title>
          <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for global impression the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory (BDI)</title>
        <description>Beck Depression Inventory (BDI) evaluation for depressive symptoms (including suicidal thoughts). The scale is completed by the participants from baseline, to last visit (all except screening visit). The questionnaire contains 21 items. Each must be scored from 0 to 3, minimum score = 0, maximum score = 63. A high score indicates increased severity of depression.</description>
        <time_frame>14 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>Beck Depression Inventory (BDI) evaluation for depressive symptoms (including suicidal thoughts). The scale is completed by the participants from baseline, to last visit (all except screening visit). The questionnaire contains 21 items. Each must be scored from 0 to 3, minimum score = 0, maximum score = 63. A high score indicates increased severity of depression.</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="5.17"/>
                    <measurement group_id="O2" value="7.0" spread="5.60"/>
                    <measurement group_id="O3" value="7.0" spread="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression for Severity (PGI-S) Global Score</title>
        <description>PGI-S us a scale filled by the participant from screening to last visit (all the visits) Participants have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
        <time_frame>14 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression for Severity (PGI-S) Global Score</title>
          <description>PGI-S us a scale filled by the participant from screening to last visit (all the visits) Participants have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>normal Not ill at all</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>borderline ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mildly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>moderately ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>markedly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>severely ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGI-C) Sleepiness</title>
        <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for sleepiness&#xD;
the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
        <time_frame>14 days after the end of treatment period I</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change (CGI-C) Sleepiness</title>
          <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for sleepiness&#xD;
the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGI-C) Cataplexy</title>
        <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for Cataplexy&#xD;
the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
        <time_frame>14 days after the end of treatment period I</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change (CGI-C) Cataplexy</title>
          <description>CGI-C (change from baseline) is a scale completed by the investigator at V3, V4 , V5 and V6 for Cataplexy&#xD;
the investigator or his/her designee has to score 3 items : global impression/ sleepiness and Cataplexy.&#xD;
For each item the investigator or his/her designee has to chose 1 condition among 7 : Very much improved/ Much improved/ Minimally improved/ No change/ Minimally worse/ Much worse/ Very much worse.&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression for Severity (CGI-S) Global Score</title>
        <description>CGI-S is a scale completed by the investigator at each visit : Item global impression&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 normal-not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among hte most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
        <time_frame>14 days after the end of treatment period I</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression for Severity (CGI-S) Global Score</title>
          <description>CGI-S is a scale completed by the investigator at each visit : Item global impression&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 normal-not ill at all/ 2 borderline ill/ 3 mildly ill/ 4 moderately ill/ 5 markedly ill/ 6 severely ill/ 7 among hte most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>normal, not ill at all</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>borderline ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>mildly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>moderately ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>markedly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>severely ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>among the most extremely ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression for Severity (CGI-S) Sleepiness</title>
        <description>CGI-S is a scale completed by the investigator at each visit for Sleepiness&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
        <time_frame>14 days after the end of treatment period I</time_frame>
        <population>modified Intent To Treat : mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression for Severity (CGI-S) Sleepiness</title>
          <description>CGI-S is a scale completed by the investigator at each visit for Sleepiness&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
          <population>modified Intent To Treat : mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Normal, not ill at all</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Borderline ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mildly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Markedly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severely ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Among the most extremely ill patients</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression for Severity (CGI-S) Cataplexy</title>
        <description>CGI-S is a scale completed by the investigator at each visit for Cataplexy&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
        <time_frame>14 days after the end of treatment period I</time_frame>
        <population>modified Intent To Treat : mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression for Severity (CGI-S) Cataplexy</title>
          <description>CGI-S is a scale completed by the investigator at each visit for Cataplexy&#xD;
CGI-S us a scale filled by the Investigator or his/her designee from screening to last visit (all the visits) Investigators have to chose 1 condition among 7 : 1 Normal-Not ill at all/ 2 Borderline ill/ 3 Mildly ill/ 4 Moderately ill/ 5 Markedly ill/ 6 severely ill/ 7 Among the most extremely ill patient&#xD;
1 is the best score (very much improved) 7 is the worse score (very much worse)&#xD;
CGI-S scale explores 3 items : Global impression/ Sleepiness/ Cataplexy</description>
          <population>modified Intent To Treat : mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Normal, not ill at all</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Borderline ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mildly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Markedly ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severely ill</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Among the most extremely ill patients</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D European Quality of Life EQ-5D (Visual Analogic Scale Part)</title>
        <description>EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).&#xD;
The EQ-5D is a questionnaire assessing the quality of life of the patient. It has two parts:&#xD;
The first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.&#xD;
The second part is a 100 mm Visual analogic scale (EQ-VAS). An higher score in VAS indicates a better health state.&#xD;
The questionnaire is assessed at baseline and all subsequent visits</description>
        <time_frame>14 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil + Placebo</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks&#xD;
Active comparator: Modafinil + placebo</description>
          </group>
          <group group_id="O2">
            <title>THN102 300/3</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks&#xD;
THN102 300/3</description>
          </group>
          <group group_id="O3">
            <title>THN102 300/27</title>
            <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks&#xD;
THN102 300/27</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D European Quality of Life EQ-5D (Visual Analogic Scale Part)</title>
          <description>EQ-5D is a quality of life questionnaire filled in by the participants from screening to the last visit (all visits).&#xD;
The EQ-5D is a questionnaire assessing the quality of life of the patient. It has two parts:&#xD;
The first part is a descriptive system that assesses five distinct health states/dimensions: Mobility (MO), Self-care (SC), Usual activities (UA), Pain/discomfort, Anxiety/depression (AD). A higher score signifies a higher number of symptoms present.&#xD;
The second part is a 100 mm Visual analogic scale (EQ-VAS). An higher score in VAS indicates a better health state.&#xD;
The questionnaire is assessed at baseline and all subsequent visits</description>
          <population>mITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.10" spread="2.600"/>
                    <measurement group_id="O2" value="66.13" spread="2.601"/>
                    <measurement group_id="O3" value="66.72" spread="2.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for each 2 week treatment period during the 3 crossover periods.</time_frame>
      <desc>Adverse events were collected by investigator - open question to patient. No scale or questionnaire based collection of events.</desc>
      <group_list>
        <group group_id="E1">
          <title>THN102 300/0</title>
          <description>Treatment A : THN102 300/0 Modafinil 300 mg/d Flecainide placebo&#xD;
Duration : 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>THN102 300/3</title>
          <description>Treatment B : THN102 300/3 Modafinil 300 mg/d Flecainide 3 mg/d Duration : 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>THN102 300/27</title>
          <description>Treatment C : THN102 300/27 Modafinil 300 mg/d Flecainide 27 mg/d Duration : 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>hunger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>sluggishness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>urinary tact infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hepatic enzyme increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>violence related symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief medical officer</name_or_title>
      <organization>Theranexus</organization>
      <phone>+33680026779</phone>
      <email>werner.rein@theranexus.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

